A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

NCT06691113 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis Without Nasal Polyps

Interventions

DRUG: Itepekimab (SAR440340)
DRUG: Placebo
DRUG: Mometasone furoate nasal spray (MFNS)

Sponsor

Sanofi

Collaborators

[object Object]